Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
Abroad (travel likely)RecruitingPHASE1
Conditions
PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Contact: Principal Investigator (Deborah Doroshow, MD, PhD)
Study leads
Deborah Doroshow, MD, PhD
Principal Investigator
Icahn School of Medicine at Mount Sinai